NBI-6024

NBI-6024, an altered peptide ligand (APL), is an epitope recognized by inflammatory interferon-gamma-producing T helper lymphocytes in type 1 diabetic patients[1][2].

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

NBI-6024 (0.005-20 mg/kg, s.c.) delays the onset and reduces the incidence of diabetes in mice[2]. Animal Model: Nonobese diabetic (NOD) mice[2] Dosage: 0.005, 0.05, 0.5, 5, 10, 20 mg/kg Administration: Subcutaneous injection (s.c.) Result: Observed dose-dependent induction of responsiveness to the immunizing antigen at 5, 10, 20 mg/kg (tested by culturing spleen cells pooled from mice).